Precision Medicine Analysis of 203 Pediatric Brain Tumors May Advance Diagnosis and Treatment
Precision medicine has advanced to the point where it can now impact the care of a majority of children with brain tumors, a new study by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center suggests.
In the largest clinical study to date of genetic abnormalities in pediatric brain tumors, researchers performed clinical testing on more than 200 tumor samples and found that a majority had genetic irregularities that could influence how the disease was diagnosed and/or treated with approved drugs or agents being evaluated in clinical trials. The findings, reported by Ramkissoon et al in Neuro-Oncology, demonstrate that testing pediatric brain tumor tissue for genetic abnormalities is clinically feasible and that, in many cases, the results can guide patients' treatment.
The need for new approaches to treating brain cancer in children is urgent, the study authors said. “Although there has been a great deal of progress over the past 30 years in improving survival rates for children with cancer, advances in pediatric brain cancer haven't been as dramatic,” said co-lead author Pratiti Bandopadhayay, MBBS, PhD, of Dana-Farber/Boston Children's. “In a recent study, brain tumors accounted for 25% of all pediatric deaths attributed to cancer. In addition, many of the current therapies can result in long-term difficulties in cognitive or physical functioning.”
Since emerging from research labs more than a decade ago, targeted therapies for cancer have significantly improved the treatment of certain types of leukemia, digestive system tumors, and breast cancer, among other malignancies. The new study is unique in that it reports on the largest collection of pediatric brain tumors to be genetically profiled as patients came to clinic.
Analysis Findings
Pathologists and cytogeneticists performed the testing in a federally approved clinical laboratory—certified under Clinical Laboratory Improvement Amendments (CLIA) as the only type of labs in the United States whose findings can guide patient treatment.
The researchers plumbed the genomes of 203 pediatric brain tumor samples, representing all major subtypes of the disease. They analyzed 117 of the samples with OncoPanel testing, a technology that sequences the exomes for irregularities in 300 cancer-related genes. They also studied 146 samples tested with OncoCopy, which examines how many copies of genes are missing or overabundant within the tumor cells. Sixty samples underwent both forms of testing, which allowed researchers to explore whether combining the two tests was more powerful than each alone.
Of the samples tested by OncoPanel, 56% harbored genetic abnormalities that were clinically relevant (44 cancer mutations and 20 rearrangements). Among other findings:
- Alterations were found in the gene BRAF, one of the most commonly mutated genes in pediatric brain tumors, and one for which several targeted drugs are being tested.
- Rearrangements in the MYB-QKI, MYBL1, BRAF, and FGFR1 genes were also detected.
- The two-pronged testing approach revealed clinically relevant abnormalities in 89% of medulloblastomas, which account for nearly a fifth of all brain tumors in children. Combining the two tests was found to be particularly useful for these patients.
“The importance of genomic profiling in the diagnosis and treatment of pediatric brain cancers is reflected in the World Health Organization's recent decision to classify such tumors by the genetic alterations within them, rather than by broad tumor type,” said study co-senior author Susan Chi, MD, of Dana-Farber/Boston Children's. “Targeted therapies are likely to be most effective when they're matched to specific abnormalities within tumor cells. Our findings show that precision medicine for pediatric brain tumors can now be a reality.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
